Antidepressant Drugs

Correct Answer

B — Aripiprazole

Rationale

Aripiprazole is classified as a dopamine D2 partial agonist and serotonin-1A partial agonist. This receptor profile distinguishes it from full dopamine antagonists such as haloperidol — as a partial agonist, aripiprazole stabilizes dopaminergic tone, acting as a functional agonist in hypodopaminergic prefrontal circuits while attenuating excess dopamine activity in mesolimbic pathways. Its augmenting antidepressant effect is attributed primarily to partial restoration of dopaminergic tone in the prefrontal cortex, which addresses residual anhedonia, low motivation, and cognitive slowing. Aripiprazole, quetiapine extended-release, brexpiprazole, and cariprazine all carry Food and Drug Administration approval for adjunctive use in major depressive disorder, but aripiprazole is specifically classified by its dual D2 and serotonin-1A partial agonism. Quetiapine augments primarily through serotonin-2A antagonism and histamine H1 blockade at low doses. Olanzapine and ziprasidone do not carry this specific classification or adjunctive major depressive disorder indication.

Correct Answer

A — Buspirone

Rationale

Buspirone is classified as a serotonin-1A partial agonist. It was one of the augmentation options studied at Step 2 of the Sequenced Treatment Alternatives to Relieve Depression trial, and its proposed mechanism of augmentation involves direct engagement of serotonin-1A autoreceptors — accelerating or enhancing the autoreceptor desensitization required for full antidepressant response. Its classification as an anxiolytic serotonin-1A partial agonist makes it most rationally applied when residual anxiety is a prominent component of partial antidepressant response. Buspirone produces no physiological dependence, no withdrawal syndrome, and no respiratory depression — pharmacological advantages over benzodiazepines in anxious patients on antidepressants. Alprazolam is a benzodiazepine gamma-aminobutyric acid-A receptor positive allosteric modulator, not a serotonin-1A partial agonist. Gabapentin modulates voltage-gated calcium channels. Propranolol is a beta-adrenergic receptor antagonist.

Correct Answer

C — Bupropion

Rationale

Bupropion is a potent cytochrome P450 2D6 inhibitor — a pharmacokinetic classification property that becomes clinically relevant when bupropion is added as an augmenting agent to a selective serotonin reuptake inhibitor that is itself a cytochrome P450 2D6 substrate. In this combination, bupropion reduces the clearance of the primary antidepressant, raising its plasma concentration and potentially increasing adverse effects. This interaction requires awareness when bupropion is added for augmentation of residual fatigue, anhedonia, or sexual dysfunction. Bupropion's norepinephrine and dopamine reuptake transporter blockade provides the pharmacodynamic rationale for augmentation; its cytochrome P450 2D6 inhibition represents a pharmacokinetic caution that must accompany that use. Mirtazapine is a weak cytochrome P450 inhibitor with no clinically significant cytochrome P450 2D6 inhibition. Venlafaxine is a cytochrome P450 2D6 substrate but has weak inhibitory activity at this isoform. Escitalopram has minimal cytochrome P450 2D6 inhibition.

Correct Answer

D — Triiodothyronine (T3)

Rationale

Triiodothyronine is the preferred thyroid hormone for antidepressant augmentation because it is biologically active as administered and does not require peripheral conversion. Thyroxine, by contrast, is the major secretory product of the thyroid gland and must be converted to triiodothyronine in peripheral tissues by deiodinase enzymes to exert its biological effects — this conversion step can be variable and inefficient in patients with illness, aging, or nutritional deficiencies. By administering triiodothyronine directly, augmentation bypasses this conversion step entirely. Thyroid hormone augmentation was included as a Step 3 option in the Sequenced Treatment Alternatives to Relieve Depression trial with a signal of efficacy; the proposed mechanism involves thyroid hormone's role in regulating central noradrenergic and serotonergic receptor sensitivity. Even thyroid-stimulating hormone levels within the normal reference range at the upper end may reflect subclinical hypothyroidism sufficient to blunt antidepressant response. Thyroid-stimulating hormone and thyrotropin-releasing hormone are regulatory hormones produced by the pituitary and hypothalamus, not thyroid hormones used therapeutically for augmentation.

Correct Answer

B — Quetiapine

Rationale

Quetiapine at low doses (25 to 200 mg) is classified as an augmenting agent whose antidepressant effect is attributed to serotonin-2A antagonism and histamine H1 blockade, not to dopamine D2 blockade. At these doses, quetiapine's dopamine receptor occupancy is minimal; it is the serotonin-2A antagonism that reduces anxiety and the histamine H1 blockade that improves sleep — two residual symptom domains frequently targeted in augmentation. Quetiapine extended-release carries Food and Drug Administration approval for adjunctive use in major depressive disorder. At antipsychotic doses, dopamine D2 blockade predominates; at augmenting antidepressant doses, the serotonin and histamine receptor effects are the operative mechanism. Haloperidol is a first-generation antipsychotic acting primarily through dopamine D2 blockade without meaningful serotonin-2A or histamine H1 classification for antidepressant augmentation. Risperidone has potent dopamine D2 and serotonin-2A blockade but lacks the histamine H1 profile that characterizes quetiapine at low doses. Lurasidone is approved for bipolar depression rather than adjunctive major depressive disorder augmentation.

Correct Answer

A — Brexpiprazole

Rationale

Brexpiprazole is classified by its combination of dopamine D2 partial agonism, serotonin-1A partial agonism, and serotonin-2A antagonism — a receptor profile that shares mechanistic features with aripiprazole but is associated with lower rates of akathisia, which has been a limiting adverse effect with aripiprazole augmentation in clinical practice. Brexpiprazole carries Food and Drug Administration approval for adjunctive use in major depressive disorder. The four atypical antipsychotics with this Food and Drug Administration indication are aripiprazole, quetiapine extended-release, brexpiprazole, and cariprazine. Cariprazine also has Food and Drug Administration approval for adjunctive major depressive disorder but is classified as a dopamine D3-preferring partial agonist, distinguishing its receptor profile from brexpiprazole. Clozapine has a broad and complex receptor profile but is not approved for adjunctive use in major depressive disorder and requires mandatory hematological monitoring for agranulocytosis. Paliperidone is the active metabolite of risperidone and does not carry this indication.

Correct Answer

D — Only approximately one-third of patients achieved remission at Step 1, and remission rates declined with each successive step, establishing the need for a prospectively planned sequential treatment strategy with optimization at each step

Rationale

The most clinically important finding of the Sequenced Treatment Alternatives to Relieve Depression trial is that only approximately 37 percent of patients achieved remission at Step 1 on citalopram — the expected pharmacological reality of major depressive disorder, not a failure of any specific drug. Cumulative remission across all four steps reached approximately 67 percent, but remission rates declined at each successive step: approximately 31 percent at Step 2, 14 percent at Step 3, and 13 percent at Step 4. Patients who required more steps were also far less likely to sustain remission during follow-up, underscoring the importance of optimizing each treatment step before moving to the next. The correct clinical implication is a prospectively planned, systematic sequential treatment strategy — not reactive switching driven by frustration or patient dissatisfaction. Because two-thirds of patients will require more than one treatment step, a plan for next-step treatment should be established at the time of initial prescribing. The trial did not establish citalopram superiority or improving remission rates across steps.

Correct Answer

C — An adequate trial requires a therapeutic dose for four to six weeks; switching at three weeks discards a treatment that may still produce remission with additional time at adequate dose

Rationale

An adequate antidepressant trial is defined as treatment at a therapeutic dose for four to six weeks — sufficient duration to assess whether the drug will produce a meaningful response. Switching before four weeks at adequate dose misses patients who would have achieved remission with additional time, because the full antidepressant response develops over weeks as receptor adaptations accumulate. At three weeks, the trial has not yet reached the minimum duration required to assess efficacy. The correct action is to confirm that the dose is within the therapeutic range and, if so, allow the trial to continue to at least four weeks before reassessing. If partial response is present at four to six weeks, dose optimization is the next step before switching. Conversely, waiting beyond eight to twelve weeks without dose optimization or a clinical reassessment constitutes an unnecessarily prolonged course of potentially ineffective treatment. Routine plasma concentration measurement is not part of standard practice for most antidepressants, and an adequate trial is not defined solely by symptom score changes at any arbitrary time point.

Correct Answer

A — Pseudo-resistance includes inadequate dosing, poor adherence, cytochrome P450 2D6 ultra-rapid metabolizer status, and unaddressed comorbidities; bipolar type II must be screened because antidepressant monotherapy can cause cycle acceleration and mixed states that mimic treatment failure

Rationale

Pseudo-resistance is apparent antidepressant treatment failure caused by correctible factors rather than true pharmacological resistance. A systematic evaluation before labeling treatment-resistant depression includes confirming adequate dosing, confirming adherence, and assessing for unaddressed comorbidities that blunt antidepressant response — hypothyroidism, obstructive sleep apnea, substance use disorders, untreated anxiety disorders, and chronic pain. Cytochrome P450 2D6 ultra-rapid metabolizer status is a pharmacogenomic cause of pseudo-resistance: standard doses produce subtherapeutic plasma concentrations in these patients, mimicking treatment failure when the drug has simply not reached effective levels. Bipolar disorder — particularly bipolar type II — requires explicit screening because patients may not recognize hypomanic episodes as abnormal and present as apparently refractory unipolar depression. Antidepressant monotherapy in bipolar depression can produce mood destabilization, cycle acceleration, and mixed states that resemble antidepressant treatment failure; the correct treatment pivot is mood stabilization, not escalation of antidepressant therapy. Only after ruling out all pseudo-resistance factors is true treatment-resistant depression appropriately diagnosed.

Correct Answer

B — Remission rates of 50 to 70 percent; indicated in severe, psychotic, suicidal, or pregnant patients; mechanism includes upregulation of brain-derived neurotrophic factor and normalization of hypothalamic-pituitary-adrenal axis activity, overlapping with antidepressant drug mechanisms

Rationale

Electroconvulsive therapy achieves remission rates of 50 to 70 percent in treatment-resistant depression populations — substantially higher than pharmacological alternatives at the same stage of treatment resistance. It is particularly indicated in patients with severe or life-threatening depression featuring psychotic features, refusal to eat or drink, or imminent suicidal risk; in pregnant patients for whom pharmacological risk is unacceptable; and in patients with known prior response to electroconvulsive therapy. Its mechanism overlaps substantially with antidepressant pharmacotherapy — electroconvulsive therapy upregulates brain-derived neurotrophic factor expression, normalizes hypothalamic-pituitary-adrenal axis hyperactivity, and produces receptor adaptations similar to those seen with chronic antidepressant pharmacotherapy. This mechanistic convergence explains why electroconvulsive therapy can succeed in patients who have failed pharmacological treatment within the same neurotrophic and neuroendocrine framework. The primary limitation is cognitive adverse effects — anterograde and retrograde memory impairment during the acute treatment course — which typically resolve within six months and are not permanent. Electroconvulsive therapy is not restricted to elderly patients and is used across the adult lifespan when clinically indicated.

Correct Answer

D — Residual fatigue, anhedonia, and cognitive slowing reflect insufficient noradrenergic and dopaminergic tone; bupropion's norepinephrine and dopamine reuptake transporter blockade directly addresses this gap, and its dopaminergic activity also mitigates selective serotonin reuptake inhibitor-induced sexual dysfunction

Rationale

The pharmacological rationale for augmentation is mechanistic: what residual deficit is the primary antidepressant not addressing, and how does the augmenting agent supply it? Selective serotonin reuptake inhibitors like escitalopram produce sustained serotonin reuptake transporter blockade that effectively addresses serotonergic deficit — but they leave noradrenergic and dopaminergic circuits relatively underactivated. Fatigue, hypersomnia, anhedonia, cognitive slowing, and low motivation are linked more closely to insufficient noradrenergic and dopaminergic tone than to residual serotonergic insufficiency. Bupropion's mechanism — inhibition of the norepinephrine and dopamine reuptake transporters with no serotonin reuptake transporter activity — precisely fills this gap, adding noradrenergic and dopaminergic enhancement to the existing serotonergic foundation of the selective serotonin reuptake inhibitor. The dopaminergic component also mitigates selective serotonin reuptake inhibitor-induced sexual dysfunction, where sustained serotonin-2A and serotonin-2C activation suppresses dopamine-mediated sexual response circuits. Bupropion does not inhibit the serotonin reuptake transporter, has no serotonin-2A antagonism, and does not block histamine H1 receptors.

Correct Answer

C — Lithium augments by enhancing serotonergic neurotransmission through increased serotonin synthesis and release and serotonin-1A receptor sensitization; target plasma concentration is 0.6 to 1.0 milliequivalents per liter; monitoring requires baseline and periodic renal and thyroid function and serum concentrations

Rationale

Lithium's proposed mechanism of antidepressant augmentation is incompletely understood but likely involves enhancement of serotonergic neurotransmission — lithium increases serotonin synthesis and release and may sensitize postsynaptic serotonin-1A receptors, effectively amplifying the serotonergic output from the primary antidepressant. Effective augmenting plasma concentrations are 0.6 to 1.0 milliequivalents per liter — within the lower therapeutic range used for bipolar disorder but still requiring the same monitoring infrastructure: baseline and periodic renal function testing (lithium is renally cleared and nephrotoxic at elevated levels), baseline and periodic thyroid function testing (lithium causes hypothyroidism in a substantial minority of patients), and regular serum concentration monitoring given lithium's narrow therapeutic index. Dehydration and sodium depletion can rapidly elevate lithium levels into the toxic range, requiring hydration counseling. Despite its extensive evidence base from controlled trials, lithium augmentation has become less commonly used in contemporary practice relative to atypical antipsychotics, primarily because of its monitoring burden. Lithium does not inhibit monoamine oxidase A, does not block dopamine D2 receptors, and does not inhibit the norepinephrine reuptake transporter as its augmenting mechanism.

Correct Answer

A — Targets the left dorsolateral prefrontal cortex — characteristically hypoactive in major depressive disorder — to increase excitability; cleared after one failed antidepressant trial; remission rates 30 to 37 percent with no cognitive adverse effects, anesthesia, or hospitalization required

Rationale

Repetitive transcranial magnetic stimulation applies alternating magnetic fields to the scalp overlying the left dorsolateral prefrontal cortex, generating focal electrical currents that increase neural excitability in a region consistently shown to be hypoactive in patients with major depressive disorder. This neurobiological target provides the mechanistic rationale for the intervention. The Food and Drug Administration has cleared transcranial magnetic stimulation for major depressive disorder in patients who have failed one prior adequate antidepressant trial — a substantially lower treatment resistance threshold than electroconvulsive therapy. Remission rates are approximately 30 to 37 percent — lower than electroconvulsive therapy's 50 to 70 percent in treatment-resistant populations — but transcranial magnetic stimulation is administered without anesthesia, without inducing a generalized seizure, and without the cognitive adverse effects (anterograde and retrograde memory impairment) that are the primary limitation of electroconvulsive therapy. It does not require hospitalization. Transcranial magnetic stimulation and antidepressant pharmacotherapy appear synergistic; continuing medications during and after the transcranial magnetic stimulation course is associated with better durability of response.

Correct Answer

B — One episode: 50 percent recurrence, continue for six to twelve months then consider tapering; two episodes: 70 percent recurrence, continue for two years; three or more episodes: 90 percent recurrence, consider indefinite maintenance

Rationale

Recurrence risk in major depressive disorder rises substantially and predictably with each additional lifetime episode — from approximately 50 percent after a first episode to approximately 70 percent after a second and approximately 90 percent after three or more. These figures provide the empirical basis for episode-count-driven maintenance guidelines. After a first episode, the recommendation is to continue the effective antidepressant for six to twelve months following remission — the natural duration of the depressive episode — before considering a gradual taper. After a second episode, two years of maintenance is recommended before considering discontinuation. After three or more episodes, or in patients with severe or suicidal episodes, a chronic course without full interepisode recovery, or a strong family history of recurrent major depressive disorder, indefinite maintenance is strongly supported by the risk-benefit calculation. In all cases, the same agent and dose that produced remission should be used for maintenance — dose reduction during continuation or maintenance increases relapse risk without proportionate benefit. Episode count and episode severity are both clinically important; episode count alone does not define the threshold when severity is extreme.

Correct Answer

C — The error is switching before dose optimization; 10 mg per day is the starting dose, not the therapeutic target, and dose titration to 20 to 40 mg per day should be the next step before declaring citalopram inadequate

Rationale

The Sequenced Treatment Alternatives to Relieve Depression trial established that optimization of the current treatment step — adequate dose at adequate duration — is the highest-priority intervention before switching. In this case, the patient has never received citalopram at a therapeutic dose: 10 mg per day is the starting dose used to minimize early adverse effects, not the therapeutic target. The standard therapeutic range for citalopram is 20 to 40 mg per day in adults under 60. The presence of partial response — improved sleep and appetite — further supports that the drug has pharmacological activity in this patient and that dose optimization may convert partial response to full remission. Switching at this point discards a potentially effective treatment before it has been adequately tested. The correct next step is dose titration to the therapeutic range, continued for four to six weeks at that dose before reassessment. Only after confirming an adequate trial at therapeutic dose — and absence of meaningful response — does switching to another agent or adding augmentation become the appropriate next step.

Correct Answer

A — Untreated obstructive sleep apnea and high-normal thyroid-stimulating hormone are pseudo-resistance comorbidities that can fully account for apparent antidepressant treatment failure; correcting them may restore antidepressant response without escalation to treatment-resistant depression interventions

Rationale

Pseudo-resistance is the term for apparent antidepressant treatment failure caused by correctible factors. Obstructive sleep apnea produces chronic sleep fragmentation, nocturnal hypoxia, and dysregulation of hypothalamic-pituitary-adrenal axis activity — each of which can independently sustain depressive symptoms and prevent antidepressant response regardless of drug selection or dose. A thyroid-stimulating hormone of 4.8 milliinternational units per liter, while within some laboratory reference ranges, may reflect subclinical hypothyroidism at the upper end of the normal range; even this level of thyroid underactivity can blunt antidepressant response by reducing the sensitivity of central noradrenergic and serotonergic receptors to which antidepressants are targeted. Treating the sleep apnea with continuous positive airway pressure and optimizing thyroid function may substantially improve or restore antidepressant response, rendering the treatment-resistant depression label inappropriate. The standard operational definition of treatment-resistant depression requires failure of two or more adequate trials — this patient meets that criterion by count, but the presence of correctible pseudo-resistance factors means the biological prerequisites for true pharmacological resistance have not been established. Cytochrome P450 2D6 testing is part of a complete pseudo-resistance evaluation but is not the most important or first step when obvious clinical comorbidities are present.

Correct Answer

D — Indefinite maintenance on the same effective dose is recommended; three or more lifetime depressive episodes are associated with approximately 90 percent recurrence risk, making long-term antidepressant therapy the appropriate risk-benefit decision

Rationale

This patient has experienced three prior depressive episodes — the threshold at which recurrence risk reaches approximately 90 percent. At this level of risk, the benefit of continued antidepressant therapy in preventing recurrent episodes substantially outweighs the risks and burdens of long-term treatment in most patients. Guidelines recommend considering indefinite maintenance therapy in patients with three or more lifetime depressive episodes, a history of severe or suicidal episodes, a chronic course without full interepisode recovery, or a strong family history of recurrent major depressive disorder. The maintenance agent and dose should be the same that produced the most recent remission — switching agents or reducing the dose during maintenance introduces pharmacological risk without demonstrated benefit. Antidepressants do not cure major depressive disorder; they suppress active episodes and reduce recurrence probability while they are being taken. Discontinuing at six to twelve months is appropriate after a first episode (50 percent recurrence risk); two years applies after a second episode (70 percent recurrence risk). Dose reduction during maintenance increases relapse risk and is not a recommended strategy to balance adverse effects against continued protection.

Correct Answer

B — Bupropion, because residual fatigue, anhedonia, and cognitive slowing after selective serotonin reuptake inhibitor therapy reflect insufficient noradrenergic and dopaminergic tone, which bupropion directly addresses through norepinephrine and dopamine reuptake transporter blockade

Rationale

Augmentation is most rationally guided by matching the augmenting agent's mechanism to the specific residual symptom pattern. Fatigue, anhedonia, cognitive slowing, and low motivation after selective serotonin reuptake inhibitor therapy are linked to insufficient noradrenergic and dopaminergic tone — not to residual serotonergic insufficiency. Sertraline addresses serotonin reuptake transporter blockade effectively, but provides no direct noradrenergic or dopaminergic enhancement. Bupropion's mechanism — inhibition of the norepinephrine and dopamine reuptake transporters with no serotonin reuptake transporter activity — precisely fills this mechanistic gap. The clinical result is increased norepinephrine and dopamine availability in prefrontal circuits governing motivation, cognitive processing speed, and reward — the circuits most relevant to her residual symptoms. Quetiapine at low doses is better matched to residual anxiety and insomnia through serotonin-2A antagonism and histamine H1 sedation, not to fatigue and cognitive slowing. Buspirone is best matched to residual anxiety via serotonin-1A partial agonism. Lithium and aripiprazole or brexpiprazole are more appropriate when no clear residual symptom pattern is present to guide mechanistic matching.